myriad genetics glp-1 receptor agonist weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies How GLP-1 Receptor Agonists Evolved

A new survey report from the International Foundation of Employee Benefit Plans reveals U.S

Do not reuse

A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D

Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.

However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects